treatment-resistant depression - Search News

US FDA approves new nasal spray for depression treatment

Popular Science · 4h

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Hosted on MSN · 1d

FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment

Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.

Wyoming News · 4h

FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had

Psychology Today4d

New Strategies for Treatment-Resistant Depression

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

Hosted on MSN44m

J&J’s Spravato receives FDA label expansion for depression monotherapy

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

J&J’s ketamine-based drug approved as standalone treatment

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results